|
[1] 汤钊猷.从生物学角度看肝癌[J].中国医学论坛报, 2007, 2:8, B5-6.
|
|
[2]Wang ZLK, Liang P, Dong BW, et al.Prognostic factors and recur-rence of small hepatocellular carcinoma after hepatic resection or mi-crowave ablation:a retrospective study[J].J Gastrointest Surg, 2008, 12 (2) :327-337.
|
|
[3]Mendez S N, Vasquez F F, Zamora VD.Sorafenib, a system thera-py for hepatocellular carcinoma[J].Ann Hepatol, 2008, 7 (1) :46-51.
|
|
[4]Simpson D, Keating GM.Sorafenib:in hepatocellular carcinoma[J].Drugs, 2008, 68 (2) :251-258.
|
|
[5]Abou-Alfa GK, Schwartz L, Ricci S, et al.PhaseⅡstudy of sor-afenib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol, 2006, 24 (26) :4293-4300.
|
|
[6]Zhu AX.Development of sorafenib and other molecularly targeted a-gents in hepatocellular carcinoma[J].Cancer, 2008, 112 (2) :250-259.
|
|
[7]Rhim H, Kim YS, Choi D, et al.Percutaneous radiofrequency abla-tion of hepatocellular carcinoma:analysis of80patients treated with two consecutive sessions[J].Eur Radiol, 2008, Apr4[Epub ahead of print].
|
|
[8]Lam VW, Ng KK, Chok KS, et al.Incomplete ablation after radio-frequency ablation of hepatocellular carcinoma:analysis of risk factors and prognostic factors[J].Ann Surg Ocol, 2008, 15 (3) :782-790.
|
|
[9]Georgiades CS, Hong K, Geschwind JF, et al.Radiofrequency abla-tion and chemoembolization for hepatocellular carcinoma[J].Cancer J, 2008, 14 (2) :117-122.
|
|
[10]Yamakado K, Nakatsuka A, Takaki H, et al.Early-stage hepato-cellular carcinoma:radiofrequency ablation combined with chemoem-bolization verus hepatectomy[J].Radiology, 2008, 247 (1) :260-266.
|
|
[11]Wong SN, Lin CJ, Lin CC, et al.Combined percutaneous radiofre-quency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J].AM j Roentgenol, 2008, 190 (3) :w187-195.
|
|
[12]Kudo M, Sakaguchi Y, Chung H, et al.Long-term interferon ma-intenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation.A matched case-control study[J].Oncology, 2007;72suppl1:32-38.
|
|
[13]Peng ZW, Zhang YJ, Chen MS, et al.Risk factors of survival afterpercutaneous radiofrequency ablation of hepatocellular carcinoma[J].Surg Oncol, 2008, 17 (1) :23-31.
|
|
[14]Choi D, Lim HK, Rhim H, et al.Percutaneous radiofrequency ab-lation for early-stage hepatocellular carcinoma as a first-line treat-ment:long term results and prognostic factors in a large single-insti-tution series[J].Eur Radiol, 2007, 73 (1-2) :684-692.
|
|
[15]Nakazawa T, Adachi S, Kitand M, et al.Potential prognostic bene-fits of radiotherapy as an initial treatment for patients with unresect-able advanced hepatocellular carcinoma with invasion to intrahepatic large vessels[J].Oncology, 2007, 73 (1-2) :90-97.
|
|
[16]You CR, Jang JW, Kang SH, et al.Efficacy of transarterial chemo-lipiodolization with or without3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis[J].Korean J Hezpa-tol, 2007, sep;13 (3) :378-386.
|
|
[17]Toya R, Murakami R, Baba Y, et al.Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma[J].Ra-diother Oncol, 2007, 84 (3) :266-271.
|
|
[18]Kim TH, Kim DY, Park JW, et al.Three-dimensional conformal radiotherapy of unrectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable[J].Am J Clin Oncol, 2006, 29 (6) :568-575.
|
|
[19]Mornex F, Girard N, Beziat C, et al.Feasibility and efficacy of high-dose three-dimonsional conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-muture results of the French phaseⅡtrial[J].Int J Radiat Oncol Biol Phys, 2006, 66 (4) :1152-1158.
|
|
[20]Wango JA, Schumacher LY, Comin-Anduis B, et al.Natural kil-ler cells play a critical role in the immune responsefollowing immuni-zation with melanoma-antigen-engineered dendritic cells[J].Cancer Gene The, 2005, 12 (6) :516-521.
|
|
[21]Cai X, Zhou J, Chang Y, et al.Targeting gene therapy for hepato-carcinoma cell with the E.coli purine nucleoside phosphorylase sui-cide gene system directed by a chimeric alpha-fetoprotein promoter[J].Cancer Lett, 2008:[Epub ahead of print]
|
|
[22]Xia D, Xu L, Fu H, et al.Recombinant adenovirus-mediated overexpression of TIMP-1effectively suppresses hepatocellular car-cinoma-cell line HepG2in vitro and in vivol[J].Zhonghua Zhong Liu Za Zhi, 2007, 29 (11) :813-817.
|
|
[23]Shen z, Yang ZF, Gao Y, et al.The kringle1domain of hepato-cyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma[J].Cancer Res, 2008, 68 (2) :404-414.
|
|
[24]Ma L, Luo L, QiaoH, et al.Complete evadication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-media-ted immunotherapy[J].J Hepatol, 2007, 46 (1) :98-106.
|
|
[25]Jacob D, Schumacher G, Bahra M, et al.Fiber-modified ade-novival vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse tran-scriptase promoter induces apoptosis in human hepatocellular carcino-ma cells[J].World J Gastroenterol, 2005, 11 (17) :2552-2556.
|
|
[26]韩铭钧, 任克, 赵仲春, 等.油性中药抗癌剂OCC肝动脉栓塞治疗肝癌84例3年随访报告[J].临床放射学杂志, 1998, 17 (2) :112-114.
|
|
[27]邵世祥, 袁海燕, 闫惠君, 等.连慈饮治疗原发性肝癌临床观察[J].实用中医内科杂志, 2005, 19 (2) :157-159.
|
|
[28]马晓红, 王小琴, 丁艳芯.中西医结合治疗原发性肝癌研究进展[J].中西医结合肝病杂志, 2007, 17 (3) :188-191.
|
PDF下载 ( 214 KB)
本文二维码
下载:
